County Durham & Tees Valley APC - NECS Medicines Optimisation

Please Note: The County Durham & Tees Valley APC became the prinicpal NHS decision making body for medicines related issues in the area covered by constituent organisations in July 2019 – superseding the Durham & Darlington APC, the Tees Medicines Governance Group and related bodies.

County Durham and Tees Valley Area Prescribing Committee

About the APC

The County Durham and Tees Valley Area Prescribing Committee (APC) is responsible for decision making and advice in relation to prescribing and medicines optimisation within services commissioned by NHS Darlington CCG, NHS Durham Dales, Easington & Sedgefield (DDES) CCG, NHS Hambleton Richmondshire & Whitby (HRW) CCG, NHS Hartlepool & Stockton on Tees (HaST) CCG, NHS North Durham CCG and NHS South Tees CCG – and/or provided by County Durham and Darlington NHS Foundation Trust (CDDFT), North Tees and Hartlepool NHS Foundation Trust (NTHFT), South Tees NHS Foundation Trust (STHFT), Tees, Esk and Wear Valleys NHS Foundation Trust (TEWV), and primary care independent contractor organisations aligned with those CCGs.

County Durham & Tees Valley Formulary

Terms of Reference, Policy Documents & Formulary Process

CD&TV APC Terms of Reference

Free-of-Charge Medicines Schemes_Adopted Policy

CD&TV Formulary Process_2019.08

Guidelines on Assigning RED / AMBER / GREEN / BLACK / GREY Status

Annual Reports

2021/22

CD&TV APC Annual Report 2021/22

2020/21

CD&TV APC Annual Report 2020/21

Formulary and New Drug Requests

The County Durham and Tees Valley APC is responsible for approval of new drugs, extending the use of existing formulary drugs to new indications and for the production of the County Durham and Tees Valley Formulary — which provides details of medicines approved for use in County Durham, Darlington, Teesside and parts of North Yorkshire. Decisions around new drug requests take into consideration safety, clinical effectiveness, and cost-effectiveness relative to other treatment options for the condition under discussion, as well as the potential available budget. Decisions will be made on fully published trial data only.